Effects of Experimental Sarcocystis neurona-Induced Infection on Immunity in an Equine Model

Table 5

Tables of significant differences in viability for (a) PMA/I and (b) merozoite stimulated cells.

(a)

Immune cell	Stimulation	Gate	Day	Time (hrs)	Change
CD4	PMA/I	Viable	7	24	Increase late apop
				72	Increase viable
CD4	PMA/I	Apop/dying	7	24	Decrease late apop
			14	24	Decrease late apop
CD8	PMA/I	Viable	7	48	Increase viable
			42	48	Increase early apop
			70	48	Increase viable
				72	Decrease early apop
Neutrophils	PMA/I	Viable	14	72	Decrease early apop
			35	24	Decrease viable
				48	Decrease late apop
			42	48	Decrease viable
Monocytes	PMA/I	Viable	21	48	Decrease late apop
			28	24	Decrease late apop
			35	24	Decrease late apop
				48	Increase early apop
				72	Increase late apop
			42	48	Decrease viable
		Viable	56	24	Decrease viable
			70	48	Increase late apop
			70	72	Increase late apop
B-cells	PMA/I	Viable	0	24	Increase late apop
			2	24	Increase late apop
			14	48	Decrease viable
			21	24	Increase viable
				72	Increase early apop
			28	24	Increase viable
			35	48	Increase late apop
			70	24	Increase early apop
		Apop/dying	21	24	Increase early apop
			35	72	Decrease viable
			70	24	Decrease late apop

(b)

Immune cell	Stimulation	Gate	Day	Time (hrs)	Change
CD4	Merozoite	Viable	35	24	Increase late apop
			70	24	Increase late apop
		Apop/dying	70	24	Increase viable
				24	Decrease early and late apop
				72	Decrease viable, increase apop
CD8	Merozoite		42	24	Increase early apop
			70	72	Increase late apop
Neutrophils	Merozoite		28	24	Decrease early apop
			56	24	Increase viable
		Viable	70		Increase viable early
					Later increase early and late apop
				72	Increase early apop
Monocytes	Merozoite		56	24	Increase viable control
			70	24	Increase late apop
B-cells	Merozoite	Live	0	24	Increase late apop
			2	48	Increase late apop
			14	48	Decrease viable
			21	24	Increase viable
				72	Increase early apop
			28	24	Increase viable
			35	48	Increase late apop
			70	24	Increase early apop
		Dying	35	72	Increase viable
			56	72	Decrease viable
			70	24	Decrease viable
				72	Increase early apop

The immune cell subset, treatment, viable/dying gate, day, time point and significant change are reported.